Navigation Links
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Date:10/20/2008

and NGX426, are the first AMPA/kainate-type glutamate receptor antagonists to be studied in clinical trials. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and NGX426 have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain, muscle spasticity, thrombosis, epilepsy and a condition known as central sensitization, a persistent state of hypersensitivity to pain that is a core component of many pain conditions.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for NGX426 as a treatment for neuropathic pain, the potential for NGX426 to be analgesic, the anticipated timing of results for the NGX426 study in a model of capsaicin-induced pain and the potential for tezampanel and
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
2. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
5. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
6. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
7. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. TorreyPines Therapeutics Reports Third Quarter 2007 Results
10. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Gene Sequencing Chemistry and Advanced Nanofluidic,Technology to Sequence Entire Human Genome in ... ... -, PHILADELPHIA, and MOUNTAIN VIEW, Calif., ... analytic platforms, and Complete Genomics Inc. (CGI), a,high- performance genome sequencing company, ...
... to Support Development of Renewable Replacement for Light ... ... 27 Solazyme, a,bioscience company pioneering biofuels and health/wellness products from,microalgae, ... Institute of Standards and Technology to develop a,biopetroleum derived from marine ...
... Using enzymes from E. coli bacteria, Duke University ... the precision of features imprinted to create microdevices such ... imprint details measuring close to 1 nanometer, or billionths ... Sept. 24, 2007 issue of the Journal of Organic ...
Cached Biology Technology:BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome 2BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome 3Solazyme Selected for National Institute of Standards and Technology Award 2Using catalysts to stamp nanopatterns without ink 2Using catalysts to stamp nanopatterns without ink 3
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... and scientist, who has spent the best part of the ... AIDS throughout the world, is calling for global strategies and ... , Quinn, a professor of infectious diseases at Hopkins and ... Infectious Disease, reports that women have in the last 20 ...
... fruit flies to people, naturally produce disease-fighting chemicals, ... a counter move, some disease-causing bacteria have evolved ... antimicrobial peptides as a warning signal. This alarm ... avoid destruction. , University of Washington (UW) and ...
... the three-dimensional terrain of a synapse -- the junction ... brain and nervous system. The "nano-map," which shows the ... one-billionth of a meter, has already proven its worth ... Using the map as a guide, the research team, ...
Cached Biology News:AIDS expert says global strategy needed to combat feminization of HIV/AIDS 2AIDS expert says global strategy needed to combat feminization of HIV/AIDS 3Bacteria recognize antimicrobials, respond with counter-defenses 2The synapse is a shotgun 2The synapse is a shotgun 3
...
... SelectFX Alexa Fluor 488 Cytochrome c Apoptosis ... need to detect cytochrome c in fixed ... primary antibody and an Alexa Fluor ... dye exhibits bright green fluorescence that is ...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
MOUSE ANTI HUMAN COMPLEMENT SC5B-9...
Biology Products: